# An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

> **NCT03501615** · — · APPROVED_FOR_MARKETING · sponsor: **AstraZeneca**

## Conditions studied

- Relapsed/Refractory Hairy Cell Leukemia

## Interventions

- **DRUG:** Moxetumomab Pasudotox

## Key facts

- **NCT ID:** NCT03501615
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501615, "An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03501615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*